BrainsWay (BWAY)

[midastouch017]

BrainsWay to Report First Quarter 2020 Financial Results and Operational Highlights on June 24, 2020

GlobeNewswire GlobeNewswire•June 9, 2020

PATTERSON, N.J. and JERUSALEM, Israel, June 09, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its first quarter 2020 financial results and operational highlights on June 24, 2020.

The Company will host a conference call at 8:30 AM Eastern Time to review the financial results and operational highlights.

To participate in the conference call, please dial one of the following numbers 10 minutes prior to the start of the call: United States: [phone]; International: [phone]; and Israel: [phone]. The access code for the call is: 6968612.

The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar. Please access the Company's website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.